Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,144
archived clinical trials in
Ocular

Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema
A Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab and Ranibizumab for Diabetic Macular Edema
Status: Enrolling
Updated:  12/31/1969
Austin Retina Associates
mi
from
Austin, TX
Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema
A Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab and Ranibizumab for Diabetic Macular Edema
Status: Enrolling
Updated: 12/31/1969
Austin Retina Associates
mi
from
Austin, TX
Click here to add this to my saved trials
Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema
A Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab and Ranibizumab for Diabetic Macular Edema
Status: Enrolling
Updated:  12/31/1969
Retina Research Center
mi
from
Austin, TX
Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema
A Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab and Ranibizumab for Diabetic Macular Edema
Status: Enrolling
Updated: 12/31/1969
Retina Research Center
mi
from
Austin, TX
Click here to add this to my saved trials
Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema
A Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab and Ranibizumab for Diabetic Macular Edema
Status: Enrolling
Updated:  12/31/1969
Retina and Vitreous of Texas
mi
from
Houston, TX
Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema
A Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab and Ranibizumab for Diabetic Macular Edema
Status: Enrolling
Updated: 12/31/1969
Retina and Vitreous of Texas
mi
from
Houston, TX
Click here to add this to my saved trials
Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema
A Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab and Ranibizumab for Diabetic Macular Edema
Status: Enrolling
Updated:  12/31/1969
Baylor Eye Physicians and Surgeons
mi
from
Houston, TX
Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema
A Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab and Ranibizumab for Diabetic Macular Edema
Status: Enrolling
Updated: 12/31/1969
Baylor Eye Physicians and Surgeons
mi
from
Houston, TX
Click here to add this to my saved trials
Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema
A Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab and Ranibizumab for Diabetic Macular Edema
Status: Enrolling
Updated:  12/31/1969
Texas Retina Associates
mi
from
Lubbock, TX
Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema
A Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab and Ranibizumab for Diabetic Macular Edema
Status: Enrolling
Updated: 12/31/1969
Texas Retina Associates
mi
from
Lubbock, TX
Click here to add this to my saved trials
Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema
A Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab and Ranibizumab for Diabetic Macular Edema
Status: Enrolling
Updated:  12/31/1969
Valley Retina Institute, P.A.
mi
from
McAllen, TX
Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema
A Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab and Ranibizumab for Diabetic Macular Edema
Status: Enrolling
Updated: 12/31/1969
Valley Retina Institute, P.A.
mi
from
McAllen, TX
Click here to add this to my saved trials
Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema
A Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab and Ranibizumab for Diabetic Macular Edema
Status: Enrolling
Updated:  12/31/1969
Retina Associates of Utah
mi
from
Salt Lake City, UT
Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema
A Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab and Ranibizumab for Diabetic Macular Edema
Status: Enrolling
Updated: 12/31/1969
Retina Associates of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema
A Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab and Ranibizumab for Diabetic Macular Edema
Status: Enrolling
Updated:  12/31/1969
Virginia Retina Center
mi
from
Leesburg, VA
Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema
A Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab and Ranibizumab for Diabetic Macular Edema
Status: Enrolling
Updated: 12/31/1969
Virginia Retina Center
mi
from
Leesburg, VA
Click here to add this to my saved trials
Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema
A Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab and Ranibizumab for Diabetic Macular Edema
Status: Enrolling
Updated:  12/31/1969
Retina Institute of Virginia
mi
from
Richmond, VA
Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema
A Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab and Ranibizumab for Diabetic Macular Edema
Status: Enrolling
Updated: 12/31/1969
Retina Institute of Virginia
mi
from
Richmond, VA
Click here to add this to my saved trials
Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema
A Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab and Ranibizumab for Diabetic Macular Edema
Status: Enrolling
Updated:  12/31/1969
University of Washington Medical Center
mi
from
Seattle, WA
Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema
A Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab and Ranibizumab for Diabetic Macular Edema
Status: Enrolling
Updated: 12/31/1969
University of Washington Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema
A Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab and Ranibizumab for Diabetic Macular Edema
Status: Enrolling
Updated:  12/31/1969
Spokane Eye Clinic
mi
from
Spokane, WA
Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema
A Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab and Ranibizumab for Diabetic Macular Edema
Status: Enrolling
Updated: 12/31/1969
Spokane Eye Clinic
mi
from
Spokane, WA
Click here to add this to my saved trials
Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema
A Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab and Ranibizumab for Diabetic Macular Edema
Status: Enrolling
Updated:  12/31/1969
University of Wisconsin-Madison, Dept of Ophthalmology/Retina Service
mi
from
Madison, WI
Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema
A Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab and Ranibizumab for Diabetic Macular Edema
Status: Enrolling
Updated: 12/31/1969
University of Wisconsin-Madison, Dept of Ophthalmology/Retina Service
mi
from
Madison, WI
Click here to add this to my saved trials
Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema
A Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab and Ranibizumab for Diabetic Macular Edema
Status: Enrolling
Updated:  12/31/1969
Retina Group of Florida
mi
from
Fort Lauderdale, FL
Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema
A Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab and Ranibizumab for Diabetic Macular Edema
Status: Enrolling
Updated: 12/31/1969
Retina Group of Florida
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema
A Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab and Ranibizumab for Diabetic Macular Edema
Status: Enrolling
Updated:  12/31/1969
Barnes Retina Institute
mi
from
Saint Louis, MO
Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema
A Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab and Ranibizumab for Diabetic Macular Edema
Status: Enrolling
Updated: 12/31/1969
Barnes Retina Institute
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema
A Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab and Ranibizumab for Diabetic Macular Edema
Status: Enrolling
Updated:  12/31/1969
Retina Vitrous Consultants
mi
from
Pittsburgh, PA
Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema
A Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab and Ranibizumab for Diabetic Macular Edema
Status: Enrolling
Updated: 12/31/1969
Retina Vitrous Consultants
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Microwave Treatment and Corneal Collagen Crosslinking for Keratoconus
A Randomized, Controlled Study of the Vedera™ KXS Microwave System With Corneal Collagen Cross-Linking Compared With Corneal Collagen Cross-Linking Alone for Eyes With Keratoconus
Status: Enrolling
Updated:  12/31/1969
Cornea and Laser Eye Institue - Hersh Vision Group
mi
from
Teaneck, NJ
Microwave Treatment and Corneal Collagen Crosslinking for Keratoconus
A Randomized, Controlled Study of the Vedera™ KXS Microwave System With Corneal Collagen Cross-Linking Compared With Corneal Collagen Cross-Linking Alone for Eyes With Keratoconus
Status: Enrolling
Updated: 12/31/1969
Cornea and Laser Eye Institue - Hersh Vision Group
mi
from
Teaneck, NJ
Click here to add this to my saved trials
Pilot Study of X-82 in Patients With Wet AMD
A Phase 1 Open-label, Dose Escalation Clinical Trial to Evaluate the Safety and Preliminary Biologic Activity/Efficacy of the VEGFR/PDGFR Inhibitor X-82 Administered Per Os in Subjects With Neovascular Age-related Macular Degeneration (AMD)
Status: Enrolling
Updated:  12/31/1969
Retina-Vitreous Associates Medical Group
mi
from
Beverly Hills, CA
Pilot Study of X-82 in Patients With Wet AMD
A Phase 1 Open-label, Dose Escalation Clinical Trial to Evaluate the Safety and Preliminary Biologic Activity/Efficacy of the VEGFR/PDGFR Inhibitor X-82 Administered Per Os in Subjects With Neovascular Age-related Macular Degeneration (AMD)
Status: Enrolling
Updated: 12/31/1969
Retina-Vitreous Associates Medical Group
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Pilot Study of X-82 in Patients With Wet AMD
A Phase 1 Open-label, Dose Escalation Clinical Trial to Evaluate the Safety and Preliminary Biologic Activity/Efficacy of the VEGFR/PDGFR Inhibitor X-82 Administered Per Os in Subjects With Neovascular Age-related Macular Degeneration (AMD)
Status: Enrolling
Updated:  12/31/1969
New England Retina Associates
mi
from
New London, CT
Pilot Study of X-82 in Patients With Wet AMD
A Phase 1 Open-label, Dose Escalation Clinical Trial to Evaluate the Safety and Preliminary Biologic Activity/Efficacy of the VEGFR/PDGFR Inhibitor X-82 Administered Per Os in Subjects With Neovascular Age-related Macular Degeneration (AMD)
Status: Enrolling
Updated: 12/31/1969
New England Retina Associates
mi
from
New London, CT
Click here to add this to my saved trials
Pilot Study of X-82 in Patients With Wet AMD
A Phase 1 Open-label, Dose Escalation Clinical Trial to Evaluate the Safety and Preliminary Biologic Activity/Efficacy of the VEGFR/PDGFR Inhibitor X-82 Administered Per Os in Subjects With Neovascular Age-related Macular Degeneration (AMD)
Status: Enrolling
Updated:  12/31/1969
Elman Retina Group, PA
mi
from
Baltimore, MD
Pilot Study of X-82 in Patients With Wet AMD
A Phase 1 Open-label, Dose Escalation Clinical Trial to Evaluate the Safety and Preliminary Biologic Activity/Efficacy of the VEGFR/PDGFR Inhibitor X-82 Administered Per Os in Subjects With Neovascular Age-related Macular Degeneration (AMD)
Status: Enrolling
Updated: 12/31/1969
Elman Retina Group, PA
mi
from
Baltimore, MD
Click here to add this to my saved trials
Pilot Study of X-82 in Patients With Wet AMD
A Phase 1 Open-label, Dose Escalation Clinical Trial to Evaluate the Safety and Preliminary Biologic Activity/Efficacy of the VEGFR/PDGFR Inhibitor X-82 Administered Per Os in Subjects With Neovascular Age-related Macular Degeneration (AMD)
Status: Enrolling
Updated:  12/31/1969
Retina Research Institute of Texas, LLC
mi
from
Abilene, TX
Pilot Study of X-82 in Patients With Wet AMD
A Phase 1 Open-label, Dose Escalation Clinical Trial to Evaluate the Safety and Preliminary Biologic Activity/Efficacy of the VEGFR/PDGFR Inhibitor X-82 Administered Per Os in Subjects With Neovascular Age-related Macular Degeneration (AMD)
Status: Enrolling
Updated: 12/31/1969
Retina Research Institute of Texas, LLC
mi
from
Abilene, TX
Click here to add this to my saved trials
Pilot Study of X-82 in Patients With Wet AMD
A Phase 1 Open-label, Dose Escalation Clinical Trial to Evaluate the Safety and Preliminary Biologic Activity/Efficacy of the VEGFR/PDGFR Inhibitor X-82 Administered Per Os in Subjects With Neovascular Age-related Macular Degeneration (AMD)
Status: Enrolling
Updated:  12/31/1969
Retina Consultants of Houston
mi
from
Houston, TX
Pilot Study of X-82 in Patients With Wet AMD
A Phase 1 Open-label, Dose Escalation Clinical Trial to Evaluate the Safety and Preliminary Biologic Activity/Efficacy of the VEGFR/PDGFR Inhibitor X-82 Administered Per Os in Subjects With Neovascular Age-related Macular Degeneration (AMD)
Status: Enrolling
Updated: 12/31/1969
Retina Consultants of Houston
mi
from
Houston, TX
Click here to add this to my saved trials
Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes
Status: Enrolling
Updated:  12/31/1969
Spectrum Medical Group
mi
from
Phoenix, AZ
Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes
Status: Enrolling
Updated: 12/31/1969
Spectrum Medical Group
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes
Status: Enrolling
Updated:  12/31/1969
5P21 Rand Schrader Clinic
mi
from
Los Angeles, CA
Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes
Status: Enrolling
Updated: 12/31/1969
5P21 Rand Schrader Clinic
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes
Status: Enrolling
Updated:  12/31/1969
University of California CARE Clinic, Los Angeles
mi
from
Los Angeles, CA
Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes
Status: Enrolling
Updated: 12/31/1969
University of California CARE Clinic, Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes
Status: Enrolling
Updated:  12/31/1969
Palmtree Clinical Research Inc
mi
from
Palm Springs, CA
Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes
Status: Enrolling
Updated: 12/31/1969
Palmtree Clinical Research Inc
mi
from
Palm Springs, CA
Click here to add this to my saved trials
Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes
Status: Enrolling
Updated:  12/31/1969
UCSD Antiviral Research Center
mi
from
San Diego, CA
Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes
Status: Enrolling
Updated: 12/31/1969
UCSD Antiviral Research Center
mi
from
San Diego, CA
Click here to add this to my saved trials
Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes
Status: Enrolling
Updated:  12/31/1969
VAMC, Infectious Disease Section 111W
mi
from
San Francisco, CA
Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes
Status: Enrolling
Updated: 12/31/1969
VAMC, Infectious Disease Section 111W
mi
from
San Francisco, CA
Click here to add this to my saved trials
Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes
Status: Enrolling
Updated:  12/31/1969
Capital Medical Associates, PC
mi
from
Washington,
Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes
Status: Enrolling
Updated: 12/31/1969
Capital Medical Associates, PC
mi
from
Washington,
Click here to add this to my saved trials
Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes
Status: Enrolling
Updated:  12/31/1969
Gary J. Richmond, M.D., P.A.
mi
from
Fort Lauderdale, FL
Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes
Status: Enrolling
Updated: 12/31/1969
Gary J. Richmond, M.D., P.A.
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes
Status: Enrolling
Updated:  12/31/1969
Triple O Research Institute, P.A.
mi
from
West Palm Beach, FL
Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes
Status: Enrolling
Updated: 12/31/1969
Triple O Research Institute, P.A.
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes
Status: Enrolling
Updated:  12/31/1969
Rowan Tree Medical, P.A.
mi
from
Wilton Manors, FL
Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes
Status: Enrolling
Updated: 12/31/1969
Rowan Tree Medical, P.A.
mi
from
Wilton Manors, FL
Click here to add this to my saved trials
Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes
Status: Enrolling
Updated:  12/31/1969
Be Well Medical Center
mi
from
Berkley, MI
Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes
Status: Enrolling
Updated: 12/31/1969
Be Well Medical Center
mi
from
Berkley, MI
Click here to add this to my saved trials
Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes
Status: Enrolling
Updated:  12/31/1969
South Jersey Infectious Disease
mi
from
Somers Point, NJ
Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes
Status: Enrolling
Updated: 12/31/1969
South Jersey Infectious Disease
mi
from
Somers Point, NJ
Click here to add this to my saved trials
Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes
Status: Enrolling
Updated:  12/31/1969
Fanno Creek Clinic
mi
from
Portland, OR
Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes
Status: Enrolling
Updated: 12/31/1969
Fanno Creek Clinic
mi
from
Portland, OR
Click here to add this to my saved trials
Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes
Status: Enrolling
Updated:  12/31/1969
Central Texas Clinical Research
mi
from
Austin, TX
Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes
Status: Enrolling
Updated: 12/31/1969
Central Texas Clinical Research
mi
from
Austin, TX
Click here to add this to my saved trials
Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes
Status: Enrolling
Updated:  12/31/1969
Dallas VA Medical Center
mi
from
Dallas, TX
Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes
Status: Enrolling
Updated: 12/31/1969
Dallas VA Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes
Status: Enrolling
Updated:  12/31/1969
UT Southwestern Medical Center, Atten: HIV Research Unit
mi
from
Dallas, TX
Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes
Status: Enrolling
Updated: 12/31/1969
UT Southwestern Medical Center, Atten: HIV Research Unit
mi
from
Dallas, TX
Click here to add this to my saved trials
Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes
Status: Enrolling
Updated:  12/31/1969
Research Access Network
mi
from
Houston, TX
Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes
Status: Enrolling
Updated: 12/31/1969
Research Access Network
mi
from
Houston, TX
Click here to add this to my saved trials
Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes
Status: Enrolling
Updated:  12/31/1969
Virginia Mason Medical Center
mi
from
Seattle, WA
Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes
Status: Enrolling
Updated: 12/31/1969
Virginia Mason Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes
Status: Enrolling
Updated:  12/31/1969
Southwest Center for HIV/AIDS
mi
from
Phoenix, AZ
Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes
Status: Enrolling
Updated: 12/31/1969
Southwest Center for HIV/AIDS
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes
Status: Enrolling
Updated:  12/31/1969
Orange County Health Department
mi
from
Orlando, FL
Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes
Status: Enrolling
Updated: 12/31/1969
Orange County Health Department
mi
from
Orlando, FL
Click here to add this to my saved trials
Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes
Status: Enrolling
Updated:  12/31/1969
Southampton Clinical Research, Inc d.b.a. Central West Clinical Research
mi
from
Saint Louis, MO
Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes
Status: Enrolling
Updated: 12/31/1969
Southampton Clinical Research, Inc d.b.a. Central West Clinical Research
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes
Status: Enrolling
Updated:  12/31/1969
Southampton Healthcare, Inc.
mi
from
Saint Louis, MO
Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes
Status: Enrolling
Updated: 12/31/1969
Southampton Healthcare, Inc.
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes
Status: Enrolling
Updated:  12/31/1969
Harold Hamm Diabetes Center at University of Oklahoma
mi
from
Oklahoma City, OK
Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes
Status: Enrolling
Updated: 12/31/1969
Harold Hamm Diabetes Center at University of Oklahoma
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes
Status: Enrolling
Updated:  12/31/1969
St. Hope Foundation
mi
from
Bellaire, TX
Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes
Status: Enrolling
Updated: 12/31/1969
St. Hope Foundation
mi
from
Bellaire, TX
Click here to add this to my saved trials
Phase III Cat-PAD Study
A Double-Blind, Randomised, Placebo-Controlled Multi-Centre Field Study to Assess the Efficacy and Safety of Cat-PAD Peptide Immunotherapy in Cat Allergic Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Colorado Springs, CO
Phase III Cat-PAD Study
A Double-Blind, Randomised, Placebo-Controlled Multi-Centre Field Study to Assess the Efficacy and Safety of Cat-PAD Peptide Immunotherapy in Cat Allergic Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Phase III Cat-PAD Study
A Double-Blind, Randomised, Placebo-Controlled Multi-Centre Field Study to Assess the Efficacy and Safety of Cat-PAD Peptide Immunotherapy in Cat Allergic Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Denver, CO
Phase III Cat-PAD Study
A Double-Blind, Randomised, Placebo-Controlled Multi-Centre Field Study to Assess the Efficacy and Safety of Cat-PAD Peptide Immunotherapy in Cat Allergic Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Denver, CO
Click here to add this to my saved trials
Phase III Cat-PAD Study
A Double-Blind, Randomised, Placebo-Controlled Multi-Centre Field Study to Assess the Efficacy and Safety of Cat-PAD Peptide Immunotherapy in Cat Allergic Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Wheat Ridge, CO
Phase III Cat-PAD Study
A Double-Blind, Randomised, Placebo-Controlled Multi-Centre Field Study to Assess the Efficacy and Safety of Cat-PAD Peptide Immunotherapy in Cat Allergic Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Wheat Ridge, CO
Click here to add this to my saved trials
Phase III Cat-PAD Study
A Double-Blind, Randomised, Placebo-Controlled Multi-Centre Field Study to Assess the Efficacy and Safety of Cat-PAD Peptide Immunotherapy in Cat Allergic Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Eagle, ID
Phase III Cat-PAD Study
A Double-Blind, Randomised, Placebo-Controlled Multi-Centre Field Study to Assess the Efficacy and Safety of Cat-PAD Peptide Immunotherapy in Cat Allergic Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Eagle, ID
Click here to add this to my saved trials
Phase III Cat-PAD Study
A Double-Blind, Randomised, Placebo-Controlled Multi-Centre Field Study to Assess the Efficacy and Safety of Cat-PAD Peptide Immunotherapy in Cat Allergic Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Meridian, ID
Phase III Cat-PAD Study
A Double-Blind, Randomised, Placebo-Controlled Multi-Centre Field Study to Assess the Efficacy and Safety of Cat-PAD Peptide Immunotherapy in Cat Allergic Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Meridian, ID
Click here to add this to my saved trials